GlassScriptPhysician profile
Abigail Gerken
NPI 1538697230
$6,569.25
in general payments reported to CMS, 2019-2025
33 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,834 · 2022: $1,016 · 2023: $1,246 · 2024: $1,273 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,623 · Education: $96.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,622.58 |
| Education | $96.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,021.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $982.08 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Biohaven Pharmaceuticals, INC. | $892.62 | 2021 | |
| Amgen INC. | $636.93 | 2021-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $334.19 | 2021-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $193.03 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Novo Nordisk INC | $188.53 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $152.20 | 2023-2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $146.73 | 2023-2025 | Loreev Xr, Gralise |
| Pfizer INC. | $108.54 | 2022-2025 | |
| Glaxosmithkline, LLC. | $107.27 | 2021-2024 | Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.46 | 2023-2025 | Caplyta |
| Currax Pharmaceuticals LLC | $93.92 | 2023-2025 | Nexletol, Contrave, Onzetra Xsail |
| Verity Pharmaceuticals INC. | $87.02 | 2024-2025 | Tlando |
| Janssen Pharmaceuticals, INC | $84.24 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $56.84 | 2023-2024 | Assurity, Gallant, Freestyle Libre 3 |
| Corium, LLC | $41.72 | 2025 | Azstarys |
| Merck Sharp & Dohme LLC | $36.94 | 2021-2025 | Capvaxive, Gardasil 9 |
| Impel Pharmaceuticals LLC | $36.22 | 2025 | Trudhesa |
| Lucid Diagnostics INC. | $33.11 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.43 | 2022-2024 | Trintellix |
| Boston Scientific Corporation | $25.09 | 2022 | |
| Lundbeck LLC | $23.10 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.24 | 2021 | |
| Sanofi Pasteur INC. | $18.48 | 2022 | |
| Mayne Pharma Commercial LLC | $18.11 | 2023 | |
| Qiagen, LLC | $17.51 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.18 | 2021 | |
| Cranial Technologies, INC | $15.30 | 2025 | Doc Band |
| Kowa Pharmaceuticals America, INC. | $14.64 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $14.34 | 2023 | Quviviq |
| Edwards Lifesciences Corporation | $13.51 | 2021 | |
| Antares Pharma, INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Gerken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.